At this year's BIO International Convention in San Diego, one topic dominated hallway conversations and panel discussions alike: the growing regulatory tension between the United States and China over biotech deal-making. As American pharmaceutical companies increasingly look to Chinese biotech firms for in-licensing deals, clinical trial partnerships, and API sourcing, policymakers in Washington are raising alarms about national security and supply chain dependency.

The backdrop is stark. Over the past five years, cross-border biotech licensing deals between US and Chinese entities have surged, with deal values exceeding $30 billion in 2025 alone. Chinese biotech companies offer compelling economics: faster clinical timelines, lower development costs, and a deep bench of chemistry and biology talent. For many small and mid-cap US pharma companies, partnering with Chinese firms is no longer a strategic luxury — it is a survival necessity.

But the political climate is shifting. Congressional committees have intensified scrutiny of so-called "outbound" biotech investments, and proposed legislation could require mandatory review of certain licensing agreements involving Chinese entities. The BIO 2026 conference served as a flashpoint for these concerns, with industry executives warning that overly restrictive policies could slow drug development timelines and cut off access to critical API intermediates.

For API and intermediate suppliers like Unibest, the implications are significant. A substantial portion of global active pharmaceutical ingredient production is concentrated in China and India. Any regulatory disruption to cross-border collaboration could ripple through the entire supply chain, affecting drug availability and pricing in Western markets. Industry analysts at BIO noted that companies with diversified sourcing strategies — including partnerships with suppliers in multiple geographies — are better positioned to weather potential regulatory storms.

The conference also highlighted a pragmatic middle ground emerging among industry leaders. Rather than decoupling entirely from Chinese biotech, many executives advocate for a "de-risking" approach: maintaining commercial relationships while diversifying critical supply lines and increasing domestic manufacturing capacity for essential medicines. This nuanced position acknowledges both the economic realities of global pharma supply chains and legitimate national security concerns.

Looking ahead, the outcome of pending legislation will shape the trajectory of US-China biotech collaboration for years to come. For pharmaceutical suppliers operating in this space, the message from BIO 2026 is clear: agility and geographic diversification are no longer optional — they are essential to long-term competitiveness. Companies that can navigate this evolving regulatory landscape while maintaining strong partnerships across borders will emerge as the winners in the next decade of global pharmaceutical innovation.